Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision

Next Previous
X
Search
Trial Profile

An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jul 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KVD 001 (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions; First in man
  • Sponsors KalVista Pharmaceuticals

    • Most Recent Events

    • 15 Jul 2019 According to the KalVista Pharmaceuticals Media Release, results of this trial were published in a financial report.
    • 15 Jul 2019 According to KalVista Pharmaceuticals Media Release, data from this trial has been accepted for publication in Ophthalmology Retina.
    • 19 May 2016 Status changed from active, no longer recruiting to completed, as reported by KalVista media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top